Artemisinin derivatives, including artesunate and artemether, are the most effective available agents for the treatment of malaria due to Plasmodium falciparum. Preservation of their usefulness, by avoidance of the emergence of malarial resistance, is of critical importance.
Vijaykadga and colleagues examined the response to treatment of infections due to P. falciparum in 9 provinces in Thailand with international borders. All patients received a single dose of primaquine on day 0; administration of all therapy was observed. The rates of response to mefloquine monotherapy, which was used in 4 provinces, were low (62%, 75%, 89.7%, and 94%). In contrast, the response rates to combination therapy with mefloquine and artesunate in a 2-day regimen (the World Health Organization recommends a 3-day regimen) ranged from 93.8% to 97.7% in 4 provinces, but the rate was only 78.6% in Trat, which borders Cambodia and where this combination of antimalarials has been used since 1995. Genotyping to confirm recrudescence, rather than reinfection, was not performed, nor was in vitro testing or mutational analysis for evidence of resistance.
Jambou and colleagues performed in vitro susceptibility testing by measurement of The highest IC 50 s of artemether detected in French Guiana and Senegal (117 nmol/ L and 45 nmol/L, respectively) were greater than the maximum values previously reported from any country. Examination of the sequences of 2 genes encoding potential artemisinin targets (Pfctp and SERCA-PfATP6) in 60 isolates identified 23 polymorphisms in the latter but none in the former. All mutations detected in isolates recovered from Cambodia were synonymous. One isolate from Senegal had 2 mutations in SERCA-PfATP6 that were associated with a very high artemether IC 50 . SERCA-PfATP6 mutations were identified in 7 isolates from French Guiana; 6 of these 7 consisted of S769N mutations. This substitution was very strongly associated with elevated artemether IC 50 s.
The current introduction of artemisinins into sub-Saharan Africa, where malaria transmission occurs at a very high rate, increases the threat of the development of resistance to this agent. This risk is especially high with its use as monotherapy. The World Health Organization has recognized this risk and has called for restriction of the availability of this class of drugs to inclusion in combination therapies [1] . It is important, however, that the agent used in combination with artemisinins also be highly active against P. falciparum in the region of use. If the protozoan is resistant to the second agent, combination therapy becomes monotherapy, with all the attendant risks of artemisinin resistance. Unfortunately, artemether resistance appears to have already reared its ugly head in French Guiana and Senegal and possibly in the Thai province of Trat. Leung and colleagues in Hong Kong retrospectively evaluated the clinical features of 19 patients with CAP due to A. baumanii. None of the patients had received either antibiotics or systemic corticosteroids in the previous 2 months, and none had been hospitalized in the previous year. The mean age of the patients with CAP due to A. baumanii was 76.2 years, and 84% of them were male; all but 1 had underlying chronic illness, 84% has smoked tobacco at some time, and almost two-thirds had chronic obstructive pulmonary disease (COPD). Most had an abrupt onset of illness and presented with severe respiratory distress. The mean WBC count was only 10,600 cells/mm 3 . Six (32%) of the 19 patients were bacteremic. The mean APACHE II score at presentation was 14.1, and 84% developed acute respiratory distress syndrome, whereas 58% required pharmacologic blood pressure support. Two-thirds of the patients received inadequate empirical antibiotic therapy. Fifty-eight percent of all patients died.
A comparison with 74 patients with hospital-acquired pneumonia due to A. baumanii found that patients with CAP due to this organism were more likely to have been smokers at some time, to have COPD, to be bacteremic, to develop acute respiratory distress syndrome and/or dis-seminated intravascular coagulation, and to die-and to do so much more quickly (mean time to death, 8 vs. 103 days).
Although only 16% of the patients with CAP in this report were known to be alcoholics, excess alcohol consumption has been suggested to be a risk factor in other studies, and a study from Darwin, Australia, found that 10% of evaluated alcoholics had pharyngeal colonization with A. baumanii [1] . Otherwise, previous studies have provided largely concordant descriptions of CAP due to this organism. Typically, the patient is elderly, has comorbidities (commonly COPD), and presents with an acute onset of febrile illness and respiratory distress. Leukocytosis may be absent, and disseminated intravascular coagulation and hypotension are common, as is the need for mechanical ventilation. The mortality rate is high.
For the patients described by Leung and colleagues who were admitted to the medical ward, the application of the current Infectious Diseases Society of American guidelines for CAP (in which Acinetobacter species are not mentioned) would lead to provision of initial empirical antibiotic therapy with "a respiratory fluoroquinolone alone or an advanced macrolide plus a b-lactam" (cefotaxime, ceftriaxone, ampicillin-sulbactam, or ertapenem) [2] . For patients who were admitted directly to an intensive care unit and who were not believed to be at risk for Pseudomonas aeruginosa infection, the recommendation is to administer one of these b-lactams together with either an advanced macrolide or a respiratory fluoroquinolone. Given the evolving resistant patterns of A. baumanii, such regimens are likely to prove to be ineffective for patients with CAP due to this organism.
